BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, has signed a manufacturing agreement with a cell therapy company based in Massachusetts.   The agreement, for an undisclosed amount, includes process development and conjugation of two antibodies in BioInvent’s development labs with work expected to start in May 2020.   Martin Welschof, chief executive officer, BioInvent, ...